Immunomodulation exerted by galectins: a land of opportunity in rare cancers.

Díaz-Alvarez, Laura; López-Cortés, Georgina I; Pérez-Figueroa, Erandi

Díaz-Alvarez, Laura; López-Cortés, Georgina I; Pérez-Figueroa, Erandi.

Afiliação

Díaz-Alvarez L; Departamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City, Mexico.
López-Cortés GI; Posgrado en Ciencias Biológicas, Unidad de Posgrado, Universidad Nacional Autónoma de México, Mexico City, Mexico.
Pérez-Figueroa E; Facultad de Química, Universidad Nacional Autónoma de México, Mexico City, Mexico.

Front Immunol ; 14: 1301025, 2023.

Article em En | MEDLINE | ID: mdl-38022609

RESUMO

Rare cancers represent only 5% of newly diagnosed malignancies. However, in some cases, they account for up to 50% of the deaths attributed to cancer in their corresponding organ. Part of the reason is that treatment options are generally quite limited, non-specific, and very often, only palliative. Needless to say, research for tailored treatments is warranted. Molecules that exert immunomodulation of the tumor microenvironment are attractive drug targets. One such group is galectins. Thus, in this review we summarize the current knowledge about galectin-mediated immunomodulation in rare cancers, highlighting the research opportunities in each case.

Assuntos

Galectinas; Neoplasias; Humanos; Neoplasias/terapia; Imunomodulação; Microambiente Tumoral

Palavras-chave

cancer; cell signaling; galectins; immunomodulation; rare cancer; therapeutics

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Galectinas / Neoplasias Limite: Humans Idioma: En Revista: Front Immunol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: México País de publicação: Suíça

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google